Clinical Trial Update: A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing SIBP-02 + Rituximab + CHOP versus a reference regimen in previously untreated CD20+ diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• SIBP-02

Snippet

Sponsor: Shanghai Institute Of Biological Products | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: COMPLETED